• ImmuPharma CEO on oversubscribed fundraising and strong 2025 outlook

  • Feb 18 2025
  • Length: 17 mins
  • Podcast

ImmuPharma CEO on oversubscribed fundraising and strong 2025 outlook

Listen for free

View show details

  • Summary

  • ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio with more on the company’s recent £2.91 million oversubscribed equity fundraising. McCarthy emphasised that this year marks a major turning point for ImmuPharma, building on extensive work from the past two to three years. The fundraising was primarily backed by long-standing investors, including Lanstead, which contributed two-thirds of the total. McCarthy highlighted that the funding will accelerate development within the company’s P140 autoimmune platform, strengthening its position in ongoing discussions with potential pharmaceutical partners. Reflecting on market sentiment, McCarthy noted the strong share price response following ImmuPharma’s January update, where the company detailed its autoimmune platform’s broad potential. The CEO also addressed the company’s structured funding agreement with Lanstead, explaining how share price performance could significantly impact the total funds received. “We have lots more news flow coming down the line,” McCarthy stated, adding that the company aims to demonstrate shareholder value creation in 2025. Watch the full interview to hear more about ImmuPharma’s strategy and future plans. Don’t forget to like this video, subscribe to Proactive’s channel, and turn on notifications for more updates. #ImmuPharma #Biotech #Investing #Pharmaceuticals #Fundraising #Autoimmune #StockMarket #BiotechStocks #TimMcCarthy #ProactiveInvestors
    Show more Show less
Show more Show less

What listeners say about ImmuPharma CEO on oversubscribed fundraising and strong 2025 outlook

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available